Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
AstraZeneca
Express Scripts
McKesson
Colorcon

Last Updated: November 28, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR IDELALISIB

➤ Subscribe for complete access

« Back to Dashboard

All Clinical Trials for IDELALISIB

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00836914 ↗ Study to Investigate Effects of CAL-101 in Subjects With Allergic Rhinitis Exposed to Allergen in an Environmental Chamber Completed Gilead Sciences Phase 1 2009-02-01 The purpose of this study is to determine the safety and effect of CAL-101 in subjects with allergic rhinitis.
NCT01088048 ↗ Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Completed Gilead Sciences Phase 1 2010-03-25 The primary objective of the study is to evaluate the safety of idelalisib in combination with an anti-CD20 monoclonal antibody (mAb), a chemotherapeutic agent, a mammalian target of rapamycin (mTOR) inhibitor, a protease inhibitor, an antiangiogenic agent, and/or an immunomodulatory agent in participants with relapsed or refractory indolent B-cell non-Hodgkin lymphoma (NHL), mantle cell lymphoma (MCL), or chronic lymphocytic leukemia (CLL).
NCT01090414 ↗ An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study Terminated Gilead Sciences Phase 1/Phase 2 2010-03-22 This is a long-term safety extension study of idelalisib (GS-1101; CAL-101) in patients with hematologic malignancies who complete other idelalisib studies. It provides the opportunity for patients to continue treatment as long as the patient is deriving clinical benefit. Patients will be followed according to the standard of care as appropriate for their type of cancer. The dose of idelalisib will generally be the same as the dose that was administered at the end of the prior study, but may be titrated up to improve clinical response or down for toxicity. Patients will be withdrawn from the study if they develop progressive disease, unacceptable toxicity related to idelalisib, or if they no longer derive clinical benefit in the opinion of the investigator.
NCT01203930 ↗ A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL Terminated Gilead Sciences Phase 2 2010-10-01 This study is to evaluate the safety and clinical activity of idelalisib alone and in combination with rituximab in patients with CLL or SLL. This Phase 2 study will be the first time that idelalisib is administered to previously untreated patients with hematologic malignancies. Idelalisib has demonstrated clinical activity as a single agent in relapsed or refractory CLL and SLL with acceptable toxicity, which supports its evaluation in previously untreated patients. The study population is limited to patients over 65 years of age because younger patients are generally appropriate for standard immunochemotherapy regimens that are highly active. Since the mechanism of action of idelalisib is distinct from rituximab, it is hypothesized that the combination will be more active than either agent alone. This study will establish initial safety and clinical activity of idelalisib in combination with rituximab in patients with CLL or SLL. Cohort 2 of this study will establish safety and clinical activity of idelalisib alone in subjects with untreated CLL or SLL.
NCT01282424 ↗ Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas Completed Gilead Sciences Phase 2 2011-03-18 The primary objective will be to assess the overall response rate and to evaluate the efficacy and safety of idelalisib (IDELA; GS-1101) in participants with previously treated indolent Non-Hodgkin Lymphoma (iNHL) that is refractory both to rituximab and to alkylating-agent-containing chemotherapy. Eligible participants will initiate oral therapy with idelalisib at a starting dose of 150 mg taken twice per day. Treatment with idelalisib can continue in compliant participants as long as the study is still ongoing and the participants appear to be benefiting from treatment with acceptable safety.
NCT01306643 ↗ Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma Completed Gilead Sciences Phase 1/Phase 2 2011-02-01 The primary objectives of this study is to evaluate the safety and efficacy of idelalisib (GS-1101, CAL-101) in participants with previously treated indolent non-Hodgkin lymphoma (iNHL). Eligible patients will initiate oral therapy with idelalisib at a starting dose of 150 mg twice per day. Treatment with idelalisib can continue in compliant participants for up to twelve 28-day cycles of idelalisib. Participants who appear to be benefiting from treatment at the completion of 12 cycles of treatment with idelalisib may be eligible for participation in a long-term safety extension study of idelalisib.
NCT01393106 ↗ Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma Completed Gilead Sciences Phase 2 2011-09-01 This study will evaluate the efficacy and safety of idelalisib in participants with relapsed of refractory Hodgkin Lymphoma (HL). The primary objective will be to assess the overall response rate. Eligible participants will initiate oral therapy with idelalisib at a starting dose of 150 mg twice daily. Treatment with idelalisib will continue until tumor progression or unacceptable toxicity.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for IDELALISIB

Condition Name

Condition Name for IDELALISIB
Intervention Trials
Chronic Lymphocytic Leukemia 20
Small Lymphocytic Lymphoma 10
Follicular Lymphoma 9
Marginal Zone Lymphoma 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for IDELALISIB
Intervention Trials
Leukemia, Lymphocytic, Chronic, B-Cell 34
Leukemia, Lymphoid 33
Leukemia 30
Lymphoma 29
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for IDELALISIB

Trials by Country

Trials by Country for IDELALISIB
Location Trials
United States 351
France 40
Australia 40
United Kingdom 32
Canada 29
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for IDELALISIB
Location Trials
New York 27
California 26
Texas 21
Washington 19
Florida 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for IDELALISIB

Clinical Trial Phase

Clinical Trial Phase for IDELALISIB
Clinical Trial Phase Trials
Phase 4 1
Phase 3 11
Phase 2 24
[disabled in preview] 22
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for IDELALISIB
Clinical Trial Phase Trials
Terminated 21
Completed 15
Active, not recruiting 14
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for IDELALISIB

Sponsor Name

Sponsor Name for IDELALISIB
Sponsor Trials
Gilead Sciences 39
National Cancer Institute (NCI) 7
OHSU Knight Cancer Institute 3
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for IDELALISIB
Sponsor Trials
Industry 55
Other 35
NIH 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
McKinsey
Boehringer Ingelheim
Dow
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.